About Restem
Restem is a company based in Corona (United States) founded in 2016 by Rafael Gonzalez. It operates as a B2B. Restem offers products and services including Restem-L, rESTEM-x, and NK Program. Restem operates in a competitive market with competitors including Nimbus Therapeutics, Escient Pharmaceuticals, Aclaris Therapeutics, Alpine Immune Sciences and Septerna, among others.
- Headquarter Corona, United States
- Founders Rafael Gonzalez
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website restem.com
Products & Services of Restem
Restem offers a comprehensive portfolio of products and services, including Restem-L, rESTEM-x, and NK Program.
Uses stem cells to treat idiopathic inflammatory myopathies.
Develops advanced cell-based treatments for various diseases.
Applies activated NK cells for immune response modulation.
People of Restem
3 people are tracked at Restem (3 in leadership).
| Name | Role | Group |
|---|---|---|
Rafael Gonzalez | Founder | Leadership |
David Pyrce | CEO | Leadership |
Brian Pla | Chief Commercial Officer (cco) | Leadership |
Complete people profiles for Restem
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Competitors of Restem
Restem operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nimbus Therapeutics, Escient Pharmaceuticals, Aclaris Therapeutics, Alpine Immune Sciences and Septerna, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | |
| escientpharma.com | 2017 | San Diego, United States | $237.5M | 44 | Small molecule therapeutics for inflammatory diseases are developed. | |
| aclaristx.com | 2012 | Malvern, United States | $82M | 180 | Novel dermatologic therapies are developed for skin conditions. | |
| alpineimmunesciences.com | 2015 | Seattle, United States | $49.25M | 126 | Developer of immunotherapies to treat cancer and autoimmune disorders | |
| septerna.com | 2020 | San Bruno, United States | $250M | – | GPCR drug discovery platform is developed for multiple diseases. | |
| calcimedica.com | 2006 | San Diego, United States | $76.66M | 11 | CRAC channel inhibitors are developed for inflammatory diseases. | |
| upstreambio.com | 2021 | Waltham, United States | $400M | – | Therapeutics for allergic and inflammatory diseases are developed. | |
| gossamerbio.com | 2017 | San Diego, United States | $330M | 102 | Developer of small molecule-based therapies for treating immunological disorders, inflammation, and cancer | |
| acelyrin.com | 2020 | Los Angeles, United States | $550M | – | Immunological drug candidates are developed for severe diseases. |
Detailed competitors of Restem
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Restem
Complete news archive for Restem
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Restem
10 companies that operate in the same segment as Restem (Cell Therapy), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 300 | |
T-cell-based immunotherapies for cancer treatment are developed. | 2000 | Tubingen, Baden-wurttemberg, Germany | USD 236.4 M | USD 54.47 M | 423 | |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. | 2015 | London, England, United Kingdom | USD 181.37 M | USD 75.56 M | 647 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 194 | |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment | 2015 | Cambridge, Massachusetts, United States | USD 158 M | – | 58 | |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | 2011 | San Francisco, California, United States | USD 36.13 M | – | 36 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Cue Biopharma is focused on developing immunotherapy solutions. | 2015 | Cambridge, Massachusetts, United States | USD 10 M | USD 27.47 M | 41 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Restem
Restem was founded in 2016.
Restem is headquartered in Corona, United States. It is registered at Corona, California, United States.
Restem specializes in harnessing umbilical cord lining stem cells and activated NK cells to modulate immune responses and treat diseases like idiopathic inflammatory myopathy and rheumatoid arthritis. The company conducts clinical trials, holds FDA designations, and focuses on scalable, off-the-shelf therapeutics. Based in the United States, Restem builds on 17 years of research to address global autoimmune challenges with innovative science and manufacturing capabilities.
Restem's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and Alpine Immune Sciences.
Restem offers Restem-L, rESTEM-x, and NK Program.